National Center for PTSD Report issue

Government Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02019940
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

National Center for PTSD

Active Ingredients

Drugs in Phase 3 Trials (1)

3,4-Methyl​enedioxy​methamphetamine (1 trial)

Drugs in Phase 2 Trials (2)

ketamine (ketalar) (1 trial)

perampanel (fycompa) (1 trial)

Drugs in Phase 1 Trials (1)

riluzole (rilutek) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stress Disorders, Post-Traumatic (Phase 1)

Stress Disorders, Traumatic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4